Raltitrexed (Tomudex™) in combination with platinum-based agents and/or anthracyclines:: Preliminary results of phase I clinical trials

被引:11
作者
Armand, JP
Seymour, L
Evans, TRJ
机构
[1] Inst Gustave Roussy, F-94805 Villejuif, France
[2] Natl Canc Inst Canada, Clin Trials Grp, Toronto, ON, Canada
[3] Univ Glasgow, Canc Res Campaign, Dept Med Oncol, Glasgow, Lanark, Scotland
关键词
raltitrexed; anthracyclines; oxaliplatin; doxorubicin; colorectal cancer; mesothelioma;
D O I
10.1016/S0959-8049(99)00043-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Three ongoing, dose-escalation, phase I studies are evaluating the combination of raltitrexed with oxaliplatin or anthracyclines (with and without cisplatin). In study 1, patients with advanced solid tumours received 2.0-3.75 mg/m(2) raltitrexed, followed 45 min later by 85-130 mg/m(2) oxaliplatin (2-h infusion) every 3 weeks. In study 2, patients with advanced oesophageal or gastric adenocarcinoma received 2.0-3.0 mg/m(2) raltitrexed with 50 mg/m(2) intravenous (i.v.) epirubicin and 60 mg/m(2) i.v. cisplatin every 3 weeks. In study 3, patients with advanced or metastatic gastric cancer received 2.5-3.5 mg/m(2) raltitrexed followed by 30-60 mg/m(2) i.v. doxorubicin every 3 weeks. In all studies, raltitrexed was given as a 15-min infusion. All the combinations evaluated were administered in convenient 3-weekly schedules and were generally well tolerated. Recommended doses for raltitrexed and oxaliplatin are the same in combination as for single-agent use, i.e. 3.0 mg/m(2) raltitrexed and 130 mg/m(2) oxaliplatin. The recommended dose of raltitrexed in combination with cisplatin and epirubicin is 2.5 mg/m(2). No dose-limiting toxicities were observed during co-administration of the full single-agent doses of raltitrexed and doxorubicin (3.0 mg/m(2) and 60 mg/m(2), respectively); dose escalation is continuing. Preliminary efficacy results were encouraging, particularly for the combination of raltitrexed and oxaliplatin in patients with mesothelioma and advanced colorectal cancer. Preliminary data from these phase I studies suggest that the combination of raltitrexed with platinum-based agents and/or anthracyclines may represent useful regimens for the treatment of patients with advanced cancer. Further studies are required to identify the most effective combinations of raltitrexed with both established and new anticancer agents. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S14 / S18
页数:5
相关论文
共 30 条
[11]  
Esaki T, 1996, INT J CANCER, V65, P479
[12]   A PHASE-II STUDY IN ADVANCED GASTROESOPHAGEAL CANCER USING EPIRUBICIN AND CISPLATIN IN COMBINATION WITH CONTINUOUS-INFUSION 5-FLUOROURACIL (ECF) [J].
FINDLAY, M ;
CUNNINGHAM, D ;
NORMAN, A ;
MANSI, J ;
NICOLSON, M ;
HICKISH, T ;
NICOLSON, V ;
NASH, A ;
SACKS, N ;
FORD, H ;
CARTER, R ;
HILL, A .
ANNALS OF ONCOLOGY, 1994, 5 (07) :609-616
[13]   INITIAL OR DELAYED CHEMOTHERAPY WITH BEST SUPPORTIVE CARE IN ADVANCED GASTRIC-CANCER [J].
GLIMELIUS, B ;
HOFFMAN, K ;
HAGLUND, U ;
NYREN, O ;
SJODEN, PO .
ANNALS OF ONCOLOGY, 1994, 5 (02) :189-190
[14]   Medical management of advanced gastric cancer [J].
Hill, ME ;
Cunningham, D .
CANCER TREATMENT REVIEWS, 1998, 24 (02) :113-118
[15]  
Huinink DT, 1998, ANN ONCOL, V9, P78
[16]  
Kaiser L R, 1997, Semin Thorac Cardiovasc Surg, V9, P383
[17]  
Machover D, 1996, ANN ONCOL, V7, P95
[18]  
Manegold C, 1998, ANN ONCOL, V9, P101
[19]  
MURAD AM, 1993, CANCER, V72, P37, DOI 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO
[20]  
2-P